Lumenis launches new radiofrequency device to treat dry eye inflammation
Click Here to Manage Email Alerts
Lumenis announced the launch of OptiPlus, its new dual-frequency radiofrequency device that delivers heat across different tissue layers to increase blood circulation and target dry eye inflammation due to meibomian gland dysfunction.
“I’m very pleased with the clinical outcomes experienced while using OptiLight to treat dry eye disease, and I’m excited about incorporating OptiPlus as an essential addition to my armamentarium,” James Chelnis, MD, FACS, ophthalmologist at Manhattan Face & Eye and leading investigator in a recently published clinical study of the two devices, said in a Lumenis press release.
According to Chelnis, the study results showed that using the two devices together improved the number of expressible meibomian glands by an average of more than 150%, meibum clarity by more than 70% and symptoms by more than 60%.
The FDA-cleared OptiPlus device promotes collagen formation and stimulates periorbital skin rejuvenation by heating the superficial layer of skin, and also reaches deeper tissue to target the meibomian glands, the release stated.
“Lumenis has a relentless commitment to innovation and eye care advancement,” Itay Mayer, Lumenis Vision’s managing director, said in the release. “We’ve driven substantial progress in the space with our gold standard OptiLight device and now with our unique dual-frequency RF technology, OptiPlus.”
Click Here to Manage Email Alerts